Basic and Clinical Research on Rett Syndrome and MECP2 (R03)

The summary for the Basic and Clinical Research on Rett Syndrome and MECP2 (R03) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Basic and Clinical Research on Rett Syndrome and MECP2 (R03): The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), the International Rett Syndrome Association (IRSA) and the Rett Syndrome Research Foundation (RSRF) invite research grant applications aimed at understanding and/or treating Rett Syndrome (RTT). The recent demonstration that mutations in the MECP2 gene cause most cases of RTT has created new opportunities for both basic and clinical research. Included within the scope of this funding opportunity announcement (FOA) with set-aside funds are developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects and clinical studies. Studies of the role of MeCP2 in basic biological processes or in the etiology of other neurological or neurobehavioral disorders are also appropriate. - This funding opportunity announcement (FOA) will utilize the NIH Small Grant (R03) award mechanism, but runs in parallel with two FOAs of identical scientific scope that utilize the traditional research project grant (R01) [PAS-05-024] and exploratory/developmental research grant (R21) [PAS-06-274] mechanisms, respectively.- The participating organizations intend to commit a total of $2,600,000 to this FOA for payment of applications responsive to this announcement and two parallel FOAs that utilize the R01 and R21 mechanisms. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Eligible organizations include For-profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Eligible agencies of the Federal government; Units of State government; Units of local government ; Foreign Institutions; Domestic Institutions; Faith-based or community-based organizations; and units of state or local tribal governments. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support -An R03 is not renewable. -Applicants may submit more than one application, provided each is scientifically distinct.